title: Double liposomes mediated dual drug targeting for treatment of Helicobacter pylori infections.
abstract: In the present study the potential of phosphatidylethanolamine (PE) lipid anchored double liposomes (DL) to incorporate two drugs in a single system is exploited as a tool to augment the H. pylori eradication rate. Preparation of DL involves two steps, first formation of primary (inner) liposomes by thin film hydration method containing one drug, then addition of suspension of inner liposomes on thin film of lipid containing the other drug. The success of formation of DL was characterized by optical and transmission electron microscopy. Quantitation of DL-bacterial interaction was evaluated in terms of percent growth inhibition (%GI) on reference strain of H. pylori ATCC 26695. To confirm specific binding efficacy of DL to H. pylori PE surface receptor we performed an agglutination assay. Agglutination in DL treated H. pylori suspension suggested selectivity of DL towards the PE surface receptor of H. pylori. Monotherapy is generally not recommended for treatment of a H. pylori infection due to the danger of development of resistance and unacceptably low eradication rates. Therefore combination therapy with amoxicillin trihydrate (AMOX) as anti-H. pylori agent and ranitidine bismuth citrate (RBC) as antisecretory agent were selected for the study with an expectation that this dual-drug delivery approach will exert acceptable anti-H. pylori activity.
authors.affiliation: Department of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur, Chattisgarh, India. yuvi2006@gmail.com
authors.forename: D Yuvraj
authors.initials: DY
authors.lastname: Singh
authors.forename: N Kamta
authors.initials: NK
authors.lastname: Prasad
mesh_terms: D000371:Agglutination; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004337:Drug Carriers; D004339:Drug Compounding; D016503:Drug Delivery Systems; D024881:Drug Resistance, Bacterial; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D007700:Kinetics; D008081:Liposomes / Q000627:therapeutic use*; D008826:Microbial Sensitivity Tests; D046529:Microscopy, Electron, Transmission; D010316:Particle Size; D010714:Phosphatidylethanolamines / Q000737:chemistry; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use; D012995:Solubility
chemical_list: D000900:Anti-Bacterial Agents; D004337:Drug Carriers; D006635:Histamine H2 Antagonists; D008081:Liposomes; D010714:Phosphatidylethanolamines; D000658:Amoxicillin; D011899:Ranitidine